DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Adherence Assessment With Travalert Dosing Aid

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Open-angle Glaucoma; Ocular Hypertension

Intervention: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Drug); Travoprost 0.004% eye drops (Drug); Timolol 0.05% eye drops (Drug); Travalert Dosing Aid (Device)

Phase: Phase 4

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Dr Francisco M. Honrubia, Study Director, Affiliation: Independent

Summary

The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0. 004%/timolol 0. 5% and patients on a concomitant combination of travoprost 0. 004% and timolol 0. 5% using the Travalert® device.

Clinical Details

Official title: Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5%

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Adherence

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of open-angle glaucoma or ocular hypertension;

- Inadequate control with beta-blocker or prostaglandin monotherapy and starting

therapy with travoprost 0. 004% and timolol 0. 05%;

- Intraocular pressure (IOP) at the screening visit in at least one eye ≥ 19 mmHg but

not exceeding 36 mmHg in either eye;

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Females of childbearing potential currently pregnant, breastfeeding, or not taking

control measures to prevent pregnancy;

- Not currently receiving treatment for lowering IOP with beta-blockers or

prostaglandin analogs;

- Currently on therapy or was in therapy with another investigational agent within 30

days prior to the baseline visit;

- History of chronic or recurrent severe inflammatory eye disease, or history of ocular

trauma within the past six (6) months, or history of ocular infection or ocular inflammation within the past three (3) months in either eye;

- History of clinically significant or progressive retinal disease or history of any

other severe ocular pathology in either eye that would preclude the administration of a topical prostaglandin analogue;

- History of severe or serious hypersensitivity to prostaglandin drugs or their

analogues, to topical or systemic beta-blockers, or to any components of the study medication;

- Intraocular surgery within the past six (6) months or ocular laser surgery within the

past three (3) months as determined by patient history and/or examination in either eye;

- Any abnormality preventing reliable applanation tonometry of either eye;

- Best-corrected visual acuity worse than 20/30 Snellen in either eye;

- Use of any additional topical or systemic ocular hyposensitive medication during the

study;

- Other protocol-defined exclusion criteria may apply.

Locations and Contacts

Zaragoza, Zaragoza 50009, Spain
Additional Information

Starting date: October 2007
Last updated: June 8, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017